MX2024005745A - Metodo para tratar la esclerosis lateral amiotrofica y la pauta posologica para la misma. - Google Patents

Metodo para tratar la esclerosis lateral amiotrofica y la pauta posologica para la misma.

Info

Publication number
MX2024005745A
MX2024005745A MX2024005745A MX2024005745A MX2024005745A MX 2024005745 A MX2024005745 A MX 2024005745A MX 2024005745 A MX2024005745 A MX 2024005745A MX 2024005745 A MX2024005745 A MX 2024005745A MX 2024005745 A MX2024005745 A MX 2024005745A
Authority
MX
Mexico
Prior art keywords
same
lateral sclerosis
amyotrophic lateral
dosing regimen
treating amyotrophic
Prior art date
Application number
MX2024005745A
Other languages
English (en)
Spanish (es)
Inventor
Sven Jacobson
Thomas Macallister
Original Assignee
Woolsey Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Woolsey Pharmaceuticals Inc filed Critical Woolsey Pharmaceuticals Inc
Publication of MX2024005745A publication Critical patent/MX2024005745A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024005745A 2021-11-12 2022-11-10 Metodo para tratar la esclerosis lateral amiotrofica y la pauta posologica para la misma. MX2024005745A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163278523P 2021-11-12 2021-11-12
PCT/US2022/049541 WO2023086468A1 (en) 2021-11-12 2022-11-10 Method of treating amyotrophic lateral sclerosis and dosing regimen for same

Publications (1)

Publication Number Publication Date
MX2024005745A true MX2024005745A (es) 2024-05-28

Family

ID=86336738

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005745A MX2024005745A (es) 2021-11-12 2022-11-10 Metodo para tratar la esclerosis lateral amiotrofica y la pauta posologica para la misma.

Country Status (7)

Country Link
US (1) US20240415846A1 (https=)
EP (1) EP4429667A4 (https=)
JP (1) JP2024543347A (https=)
CN (1) CN118251226A (https=)
CA (1) CA3236338A1 (https=)
MX (1) MX2024005745A (https=)
WO (1) WO2023086468A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025207476A1 (en) * 2024-03-25 2025-10-02 Woolsey Pharmaceuticals, Inc. Methods for treating als with a rho kinase inhibitor based on use of neurofilament light chain biomarker

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050783A2 (en) * 2005-10-26 2007-05-03 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
US9980972B2 (en) * 2012-03-12 2018-05-29 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Rho kinase inhibitors for use in treating familial amyotrophic lateral sclerosis
US20180055887A1 (en) * 2016-08-23 2018-03-01 Academia Sinica Method for preparing induced mesenchymal stem cells and improving mesenchymal stem cell's characters and its applications
US11642352B2 (en) * 2020-03-25 2023-05-09 Woolsey Pharmaceuticals, Inc. Methods of treating wandering in Lewy dody dementia

Also Published As

Publication number Publication date
CN118251226A (zh) 2024-06-25
EP4429667A1 (en) 2024-09-18
CA3236338A1 (en) 2023-05-19
US20240415846A1 (en) 2024-12-19
WO2023086468A1 (en) 2023-05-19
JP2024543347A (ja) 2024-11-21
EP4429667A4 (en) 2025-09-17

Similar Documents

Publication Publication Date Title
CL2023000846A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
MX2023007853A (es) Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo.
TN2022000113A1 (en) Dosing regimen for anti-dll3 agents
CO6311006A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas
CO2020004034A2 (es) Métodos para el tratamiento de distrofia muscular
BR112022005059A2 (pt) Composições para tratamento bucal com atividade anticárie
HRP20220277T1 (hr) Liječenje fragilnog x sindroma i autizma kanabidiolom
CL2021002437A1 (es) Métodos para tratar la distrofia muscular con casimersin
BR112023001792A2 (pt) Combinações para o tratamento de câncer
JOP20230278A1 (ar) تركيبة صيدلانية للوقاية من التليف أو علاجه
MX2024005745A (es) Metodo para tratar la esclerosis lateral amiotrofica y la pauta posologica para la misma.
MX2025002439A (es) Compuestos ciclicos de urea tiazolilo para el tratamiento del hsv
MX2024004131A (es) Ciertos 2,5-diazabiciclo[4.2.0]octanos como moduladores del receptor de glp-1.
MX2023000868A (es) Derivado de isoindolina que contiene azufre, metodo de preparacion y uso medico del mismo.
ECSP13012650A (es) Métodos y composiciones para tratar diarrea asociada con vih
CL2024002763A1 (es) Dosificación no lineal de mirdametinib
MX2023006366A (es) Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
Halperson et al. Dental pulp therapy for primary teeth in children undergoing cancer therapy
CO2024017693A2 (es) Regímenes de dosis para tratamiento de infección de dengue
MX2025005378A (es) Metodos para el tratamiento de enfermedades cardiovasculares
CL2025001708A1 (es) Esquema de dosificación de una dispersión sólida de un inhibidor de her2
PE20240777A1 (es) Proteinas actrii y usos de las mismas
MX2025002288A (es) Formulacion farmaceutica y regimen de dosificacion para el tratamiento de la esclerosis lateral amiotrofica
MX2022011651A (es) Composicion farmaceutica para tratamiento de diabetes.
Gupta et al. Role of tamoxifen and danazol in mastalgia: prospective controlled trial